Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First Clinical Feasibility Study Using the CellFX® Percutaneous Electrode (PE) System for the Treatment of Symptomatic Benign Thyroid Nodules

NCT06117085 is registered in ClinicalTrials.gov with Pulse Biosciences, Inc. as lead sponsor.

NCT NCT06117085
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06117085 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First Clinical Feasibility Study Using the CellFX® Percutaneous Electrode (PE) System for the Treatment of Symptomatic Benign Thyroid Nodules
Lead sponsor
Pulse Biosciences, Inc.
Phase
Not applicable
Overall status
Completed
Start date
April 13, 2023
Completion date
November 18, 2024
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

thyroid nodule (benign)